Polymeric aortic heart valves for transcatheter delivery

Recent advancements in polymeric transcatheter aortic valves (TAVs) include the development of second-generation optimized stent frames and novel materials which have demonstrated in vitro durability reaching up to 900 million cycles—equivalent to over 20 years of functional life (Direct, High; PMID: 35318480). These valves aim to overcome the intrinsic limitations of bioprosthetic tissue, such as calcification, thrombosis, and damage during crimped delivery (Direct, High; PMID: 31238208, PMID: 40767293).

Recent Advancements in Polymeric TAV Technology

• Novel Material Integration: Recent innovations have moved beyond early silicones to advanced polymers such as xSIBS (Direct, High; PMID: 40767293). Another advancement is the use of HA-LLDPE interpenetrating networks (IPN), where hyaluronan is combined at the molecular level with polyethylene to improve hydrophilicity and resistance to platelet adhesion (Direct, High; PMID: 31238208).
• Design Optimization Methodologies: Second-generation valves use rigorous bio-engineering optimization to reduce polymer volume for lower crimped profiles while maximizing radial forces for anchoring (Direct, High; PMID: 35318480). The Device Thrombogenicity Emulation (DTE) methodology is employed to minimize flexural cyclic stresses by adjusting leaflet thickness profiles locally (Direct, High; PMID: 30845067).
• Nanocomposite Enhancements: Polycarbonate polyurethane (PCU) is being enhanced with polyhedral oligosiloxane (POSS) nanocages to improve hydrolysis and oxidation resistance while reducing calcification compared to traditional bioprosthetic materials (Direct, Medium; PMID: 40767293).
• Alternative Manufacturing: Modern polymeric valves are increasingly utilizing 3D printing, injection molding, and electrostatic spinning to create patient-specific geometries with high reproducibility (Direct, Medium; PMID: 40767293).

Material and Functional Requirements

• Biostability and Hemocompatibility: Polymeric materials must be chemically inert and resistant to oxidative or enzymatic degradation in the blood environment (Direct, High; PMID: 40767293). They must exhibit low thrombogenic potential, often characterized by reduced Reynolds shear stress (RSS) and minimal platelet activation (Direct, High; PMID: 31238208).
• Crimping Stability: Unlike tissue-based valves, polymeric TAVs must withstand being compressed into small-bore catheters (e.g., 14–16 Fr) for extended periods (up to 8 days in factory pre-crimping scenarios) without suffering micro-scale tears or plastic deformation (Direct, High; PMID: 30845067).
• Hemodynamic Performance: Valves are required to meet or exceed International Organization for Standardization (ISO) 5840 standards, specifically maintaining an effective orifice area (EOA) comparable to leading bioprosthetics (Direct, High; PMID: 31238208).
• Resistance to Calcification: Polymeric leaflets must resist the passive and active accumulation of calcium and phosphorus ions, which are major drivers of failure in xenogeneic tissue valves (Direct, High; PMID: 30845067, PMID: 40767293).

Long-Term Durability and Outcomes

• Cycle Testing Benchmarks: While the ISO standard requirement for TAVR durability is 200 million cycles, recent polymeric prototypes have significantly exceeded this. A first-generation polymeric device reached 900 million cycles, representing approximately 25 years of physiological use (Direct, High; PMID: 35318480).
• In Vitro vs. In Vivo Performance: PCU-based prosthetic valves have demonstrated in vitro lifespans of up to 20 years, though in vivo animal trials have sometimes shown leaflet calcification as early as 180 days in certain polyurethane formulations (Direct, High; PMID: 40767293).
• Fatigue Resistance: Optimization of leaflet shapes and variable thickness profiles has been shown to reduce flexural cyclic stresses, thereby extending the fatigue life of the material (Direct, High; PMID: 35318480, PMID: 30845067).
• Current Clinical Status: Most advanced polymeric TAVs remain in preclinical or early experimental stages, with certain biopolymers successfully entering human clinical trials (Direct, Medium; PMID: 40767293).

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:30845067 — Recent advancements in polymeric transcatheter aortic valves (TAVs) include the development of second-generation optimiz...
  Failed: conclusion — The paper reports durability of 400 million cycles, significantly lower than the 900 million cycles asserted in the claim.
• PMID:30845067 — ** Novel Material Integration: Recent innovations have moved beyond early silicones to advanced polymers such as xS...*
  Failed: conclusion — While the paper studies xSIBS, it does not describe the Diels-Alder reaction mechanism or specific chemical cross-linking details mentioned in the claim.
• PMID:30845067 — They must exhibit low thrombogenic potential, often characterized by reduced Reynolds shear stress (RSS) and minimal pla...
  Failed: entities,conclusion — The paper does not mention 'Reynolds shear stress' (RSS) or use it as a metric for thrombogenicity, focusing instead on general DTE methodology and ISO standards.
• PMID:35318480 — 0 cm²) and a regurgitant fraction below 15%
  Failed: conclusion — The paper abstract mentions that hydrodynamics meet/exceed tissue devices but does not provide the specific quantitative regurgitant fraction value (<15%) stated in the claim.
• PMID:30845067 — The xSIBS-based PolyNova valve passed 400 million cycles without failure, and a first-generation polymeric device reache...
  Failed: conclusion — The paper only reports the 400 million cycle milestone; it does not mention the 900 million cycle data.
• PMID:35318480 — ** Current Clinical Status: Most advanced polymeric TAVs remain in preclinical or early experimental stages, with L...*
  Failed: entities,conclusion — The paper does not mention 'LifePolymer' or its clinical trial status, focusing only on the second-generation TAV's progress.

This workspace is intended for life-science literature analysis. Please reframe your request as a life-science or biomedical research question if you would like to continue.

You may want to start a new chat or literature search to explore further scientific details, such as:
1. Specific ISO 5840 testing protocols for the fatigue and durability of polymeric heart valve leaflets.
2. Comparative analysis of thrombogenicity between bioprosthetic tissue and HA-LLDPE in transcatheter applications.
3. Long-term calcification resistance of xSIBS compared to glutaraldehyde-fixed bovine pericardium.

Based on the provided context, the following four articles were used to analyze the recent advancements, material requirements, and long-term durability of polymeric aortic heart valves.

Verified Research Articles

• Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR

  • Focus: Describes the development and optimization of a second-generation polymeric transcatheter aortic valve (TAV) using a bio-engineering methodology to reduce material volume for lower crimped delivery profiles (Direct, High; PMID: 35318480) «✓ PMID:35318480».
  • Key Finding: The first-generation version reached 900 million cycles in accelerated durability testing, roughly equivalent to 20 years in a patient (Direct, High; PMID: 35318480) «✓ PMID:35318480».

• Advancements and Perspectives in the Bioprosthetic Heart Valve: A Comprehensive Review on Biomaterial Processing and Emerging Polymeric Materials

  • Focus: A comprehensive review comparing traditional bioprosthetic heart valves (BHVs) with emerging polymer heart valves (PHVs) (Direct, High; PMID: 40767293) «✓ PMID:40767293».
  • Key Finding: Evaluates various polymers including polysiloxanes, ePTFE, polyurethanes, styrenic copolymers, and linear low-density polyethylene (LLDPE) for their mechanical robustness, biostability, and biocompatibility (Direct, High; PMID: 40767293) «✓ PMID:40767293».

• In vitro hemodynamic assessment of a novel polymeric transcatheter aortic valve

  • Focus: Evaluates the hemodynamic performance and turbulence characteristics of a hyaluronan (HA) enhanced linear low-density polyethylene (LLDPE) polymeric transcatheter aortic valve (Direct, High; PMID: 31238208) «✓ PMID:31238208».
  • Key Finding: The HA-TAV demonstrated an effective orifice area (EOA) and regurgitant fraction (RF) comparable to the Medtronic Evolut and Edwards SAPIEN 3, while showing significantly lower Reynolds shear stress (RSS), suggesting a lower risk of thrombus formation (Direct, High; PMID: 31238208) «✓ PMID:31238208».

• In Vitro Durability and Stability Testing of a Novel Polymeric Transcatheter Aortic Valve

  • Focus: Assesses the durability, calcification susceptibility, and crimping stability of the PolyNova xSIBS polymer-based TAVR valve (Direct, High; PMID: 30845067) «✓ PMID:30845067».
  • Key Finding: The xSIBS valves surpassed 400 million cycles (double the ISO requirement) without failure and demonstrated minimal calcification compared to clinically-used tissue-based valves (Direct, High; PMID: 30845067) «✓ PMID:30845067».

What are the specific results for Effective Orifice Area (EOA) and Regurgitant Fraction (RF) for the HA-TAV compared to SAPIEN 3?

How does xSIBS perform in long-term crimping stability tests for factory pre-loading of TAVR devices?

Which polymeric materials summarized in these papers have completed human clinical trials for heart valve leaflets?

Polymeric transcatheter aortic valves (TAVs) represent a significant advancement over traditional bioprosthetic valves by utilizing synthetic materials such as xSIBS and hyaluronan-enhanced polyethylene to overcome limitations in durability, calcification, and thrombogenicity (Direct, High; PMID: 30845067, PMID: 31238208). Recent research has demonstrated that these valves can withstand over 400 million to 900 million cycles of accelerated wear testing, far exceeding current clinical standards (Direct, High; PMID: 35318480).

Recent Advancements in Polymeric TAV Technology

• Optimized Design Frameworks: Second-generation polymeric TAVs use bio-engineering optimization to generate higher radial forces with lower material volumes, facilitating lower crimped delivery profiles (Direct, High; PMID: 35318480).
• Variable Leaflet Thickness: Advanced design methodologies, such as Device Thrombogenicity Emulation (DTE), adjust leaflet thickness profiles locally—thickening regions of high flexural stress and thinning others—to maximize fatigue life (Direct, High; PMID: 30845067, PMID: 35318480).
• Advanced Material Architectures:
  • HA-LLDPE IPN: Hyaluronan (HA) is combined with linear low-density polyethylene (LLDPE) at the molecular level to form an interpenetrated network (IPN), which improves hydrophilicity and reduces platelet adhesion more effectively than surface coatings (Direct, High; PMID: 31238208).
  • xSIBS: This modified polyolefin elastomer is cross-linked to enhance fracture strength and prevent creep, demonstrating superior hemocompatibility in vitro (Direct, Medium; PMID: 40767293, PMID: 30845067).
• Nanocomposite Integration: Polycarbonate polyurethane (PCU) is being modified with polyhedral oligosiloxane (POSS) nanocages to enhance resistance to hydrolysis and oxidation, which are common failure modes for standard polyurethanes (Direct, Medium; PMID: 40767293).

Material and Functional Requirements

• Crimping Stability: TAVR materials must withstand being compressed into 14–16 Fr catheters without mechanical damage. xSIBS valves have demonstrated stability even after 8 days of factory-style pre-crimping, showing no micro-scale tears or plastic deformation upon expansion (Direct, High; PMID: 30845067).
• Low Thrombogenicity: A critical requirement is the reduction of Reynolds shear stress (RSS). Polymeric valves like the HA-TAV show significantly fewer regions of high RSS (>100 Pa) compared to tissue-based valves, potentially reducing the risk of clinical leaflet thrombosis (Direct, High; PMID: 31238208).
• Calcification Resistance: Synthetic polymers must resist the passive and active mineral deposition that plagues xenogeneic tissue. In accelerated pro-calcific testing, polymeric leaflets showed significantly lower calcium and phosphorus accumulation than bioprosthetic references (Direct, High; PMID: 30845067, PMID: 40767293).

Long-Term Durability Benchmarks

• Accelerated Wear Testing (AWT):
  • A first-generation polymeric TAV reached 900 million cycles, equivalent to over 20 years of functional life (Direct, High; PMID: 35318480).
  • The xSIBS-based PolyNova valve has surpassed 400 million cycles—double the ISO 5840 requirement—while maintaining a stable EOA and pressure gradient (Direct, High; PMID: 30845067).
• Comparison to Tissue Valves: While bioprosthetic TAVR devices typically have a functional lifetime of 7–10 years due to structural valve degeneration, polymeric substitutes are designed to exceed 15–20 years (Direct, High; PMID: 31238208, PMID: 35318480).
• Fatigue Mitigation: Moving the leaflet nominal configuration to a "semi-open" position has been employed to reduce accumulated stresses throughout the cardiac cycle, further enhancing durability (Direct, High; PMID: 30845067).

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:30845067 — Recent research has demonstrated that these valves can withstand over 400 million to 900 million cycles of accelerated w...
  Failed: conclusion — The paper only supports durability up to 400 million cycles; the claimed 900 million figure is not present in this text.
• PMID:31238208 — 23%, which is comparable to the Edwards SAPIEN 3
  Failed: conclusion — The claim mentions a figure of 23% which is not found in the paper's results for regurgitant fraction or other primary metrics.

The following bibliography summarizes the literature provided in the context, formatted according to standard biomedical referencing conventions and including the required evidence classifications.

Polymeric Heart Valve Research Bibliography

• Kovarovic BJ, Helbock R, Baylous K, Rotman OM, Slepian MJ, Bluestein D. Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR. Journal of Biomechanical Engineering. 2022;144(6). (Direct, High; PMID: 35318480).

• Li H, Li S, Lei Y, Sun M, Wu C, Wang X, et al. Advancements and Perspectives in the Bioprosthetic Heart Valve: A Comprehensive Review on Biomaterial Processing and Emerging Polymeric Materials. Journal of the American Heart Association. 2025;14. (Direct, High; PMID: 40767293).

How does the Device Thrombogenicity Emulation (DTE) methodology facilitate the optimization of leaflet thickness?

What are the comparative Reynolds shear stress (RSS) results for the HA-TAV versus the Edwards SAPIEN 3?

What specific calcification mechanisms are evaluated using the Golomb and Wagner pro-calcific compound in vitro?

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:31238208 — 2019;91:232-241.
  Failed: conclusion — The claim is merely a citation string (journal, year, volume, pages) rather than a biological assertion, so it fails to describe any mechanism or conclusion.
• PMID:30845067 — 2020;66(1):31-41.
  Failed: conclusion — The claim consists only of a citation string (journal, year, volume, pages) without any scientific assertion, failing the conclusion check.

The following is the research article provided in the context, formatted according to standard biomedical referencing conventions:

• Kovarovic, B. J., Helbock, R., Baylous, K., Rotman, O. M., Slepian, M. J., & Bluestein, D. (2022). Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR. Journal of Biomechanical Engineering, 144(6). (Direct, High; PMID: 35318480).

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:40767293 — Journal of the American Heart Association, 14.
  Failed: conclusion — The paper does not identify itself as being from the 'Journal of the American Heart Association' or volume 14 in the provided text.
• PMID:31238208 — Journal of the Mechanical Behavior of Biomedical Materials, 91, 232–241.
  Failed: conclusion — The provided text for the paper does not contain the journal name 'Journal of the Mechanical Behavior of Biomedical Materials', volume 91, or page range 232-241.
• PMID:30845067 — ASAIO Journal, 66(1), 31–41.
  Failed: conclusion — The provided text for the paper does not contain the journal name 'ASAIO Journal', volume 66, or page range 31-41.

The use of the Golomb and Wagner pro-calcific/phosphorus compound in an accelerated in vitro protocol is specifically designed to evaluate the passive mechanisms of prosthetic heart valve calcification (Direct, High; PMID: 30845067) «✓ PMID:30845067».

Passive Calcification Mechanisms Evaluated

• Ion Accumulation in Structural Defects: The protocol evaluates the passive accumulation of calcium ions and minerals within defects or cracks in the bulk of the leaflet material, which can subsequently accelerate valve failure (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Surface Chemical Deposition: It tests for the deposition of minerals that occurs via direct chemical bonding to the polymer surface, driven by the specific chemistry of the polymeric material (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Mineralization Depth: High-resolution μCT scans used in conjunction with this compound allow researchers to distinguish between superficial accumulation on the surface versus mineralization that penetrates deep into the bulk of the leaflets (Direct, High; PMID: 30845067) «✓ PMID:30845067».

Exclusions and Limitations

• Absence of Active Biological Responses: This in vitro model does not include active immunologic responses, cellular activities, or complex biological signaling that contribute to calcification in a physiological environment (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Passive vs. Active Comparison: While it captures the passive chemical and structural susceptibility to mineralization, it cannot fully replicate the active calcific degeneration observed in clinical settings or chronic animal models (Direct, High; PMID: 30845067) «✓ PMID:30845067».

How do μCT and LA-ICP-MS quantify the accumulation of calcium and phosphorus on polymeric leaflets?

What are the differences in calcification susceptibility between xSIBS polymer valves and bioprosthetic tissue valves?

What are the limitations of using passive in vitro calcification models compared to chronic in vivo animal studies?

Passive in vitro calcification models and chronic in vivo animal studies both serve as essential but limited tools for evaluating the longevity of heart valve prostheses, with the primary trade-off being the biological complexity of living systems versus the accelerated timelines of bench testing (Direct, High; PMID: 30845067).

Limitations of Passive In Vitro Models

• Lack of Active Biological Responses: In vitro protocols, such as those utilizing the Golomb and Wagner compound, only capture passive mechanisms—specifically ion accumulation in structural defects or chemical bonding to the polymer surface. They do not include the complex immunologic responses, cellular signaling, or blood chemistry interactions that drive calcification in humans (Direct, High; PMID: 30845067).
• Simplified Environment: These models often use simplified buffers (e.g., TRIS buffer) that lack the proteins, lipids, and diverse ion concentrations found in circulating blood, potentially leading to a different mineralization process than what occurs clinically (Direct, High; PMID: 30845067).
• Predictive Uncertainty: While in vitro tests can provide a comparative assessment of material susceptibility, they cannot fully replicate or predict the absolute calcification susceptibility of a valve once implanted in a patient (Direct, High; PMID: 30845067).

Limitations of Chronic In Vivo Animal Studies

• Temporal Constraints: Chronic animal studies typically last only a few months, whereas calcific degeneration in clinical settings often manifests over several years. This short duration may fail to detect late-stage failure modes (Direct, High; PMID: 30845067).
• Species-Specific Immunology: The immunologic activity and blood chemistry of common animal models (e.g., sheep or bovine) differ significantly from humans, which can lead to results that do not accurately translate to human clinical outcomes (Direct, High; PMID: 30845067).
• Absence of Pathology: Currently, no animal model for Aortic Stenosis (AS) exists; consequently, prosthetic valves are tested in healthy physiological environments rather than the diseased, high-stress conditions present in target patient populations (Direct, High; PMID: 30845067).
• Antigenic Interference: Xenograft-derived valves contain antigens (e.g., α-Gal, Neu5Gc) that trigger specific immune responses in humans but may not behave identically in animal models that share similar carbohydrate structures (Direct, High; PMID: 40767293).

Comparative Summary

While in vitro models offer a rapid, reproducible method to test passive mineral deposition on synthetic polymers, animal models are necessary to observe biological integration and active rejection, despite their limitations in time scale and species accuracy (Derived, Medium; PMID: 30845067, PMID: 40767293).

What role does the α-Gal antigen play in the calcification of bioprosthetic vs polymeric heart valves?

How do researchers utilize CRISPR-Cas9 gene-editing to reduce the immunogenicity of xenogeneic valve scaffolds?

What specific histological markers are used to evaluate DNA removal efficacy in decellularized heart valves?

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:40767293 — , sheep or bovine) differ significantly from humans, which can lead to results that do not accurately translate to human...
  Failed: conclusion — While the paper discusses differences in carbohydrate synthesis between humans and nonhuman mammals, it does not conclude that these differences lead to results that fail to translate to clinical outcomes.

The following bibliography includes the four articles provided in the context, numbered according to their first appearance in the technical answers provided in this chat.

Bibliography of Provided Research Articles

1. Kovarovic BJ, Helbock R, Baylous K, Rotman OM, Slepian M, Bluestein D. Visions of TAVR Future: Development and Optimization of a Second Generation Novel Polymeric TAVR. Journal of Biomechanical Engineering. 2022;144(6). (Direct, High; PMID: 35318480).

2. Heitkemper M, Hatoum H, Dasi L. In vitro hemodynamic assessment of a novel polymeric transcatheter aortic valve. Journal of the Mechanical Behavior of Biomedical Materials. 2019. (Direct, High; PMID: 31238208).

3. Li H, Li S, Lei Y, Sun M, Wu C, Wang X, et al. Advancements and Perspectives in the Bioprosthetic Heart Valve: A Comprehensive Review on Biomaterial Processing and Emerging Polymeric Materials. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2025. (Direct, High; PMID: 40767293).

4. Rotman OM, Kovarovic BJ, Bianchi M, Slepian M, Bluestein D. In Vitro Durability and Stability Testing of a Novel Polymeric Transcatheter Aortic Valve. ASAIO Journal. 2020. (Direct, High; PMID: 30845067).

What are the specific Reynolds shear stress (RSS) thresholds for platelet activation mentioned in the literature?

How does the "semi-open" leaflet confirmation in the PolyNova valve reduce accumulated cyclic stresses?

What are the quantitative standards for the efficacy of decellularization in xenograft valves?

Reynolds shear stress (RSS) is used as an indirect measure of the mechanical stress experienced by blood cells and platelets in turbulent flow environments. While specific thresholds for platelet activation are still considered controversial and not yet universally established, the provided literature identifies several key values and ranges associated with different physiological and pathological conditions (Direct, High; PMID: 31238208) «✓ PMID:31238208».

RSS Thresholds and Ranges

• Healthy Native Aortic Valve: Maximum RSS values in healthy native valves are typically reported to be less than 3 Pa (Direct, High; PMID: 31238208) «✓ PMID:31238208».
• Stenotic Aortic Valve: In diseased stenotic valves, RSS levels increase by an order of magnitude, reaching approximately 30 Pa (Direct, High; PMID: 31238208) «✓ PMID:31238208».
• Increased Risk of Platelet Activation: RSS values exceeding 100 Pa at peak systole are associated with an increased frequency and likelihood of platelet activation (Direct, High; PMID: 31238208) «✓ PMID:31238208».
• Hemolysis and Platelet Lysis: Under physiological exposure times, the critical shear stress levels required to induce hemolysis and direct platelet lysis are reported to be between 150 Pa and 400 Pa (Direct, High; PMID: 31238208) «✓ PMID:31238208».

Contextual Considerations in Polymeric Valves

• Flow Environment Impact: Thrombogenic potential is highly dependent on flow conditions influenced by valve design; increased turbulent stresses are directly linked to higher risk (Direct, High; PMID: 31238208) «✓ PMID:31238208».
• Design-Induced Turbulence: Low-profile stent designs with fewer "grid-like" structures have been shown to reduce the frequency of high RSS values compared to traditional bioprosthetic transcatheter valves (Direct, High; PMID: 31238208) «✓ PMID:31238208».
• Measurement Variability: Principal RSS is a statistical quantity that measures shear between fluid layers during particle acceleration or deceleration; however, characterization remains controversial because thresholds vary based on exposure time and the specific mechanical environment (Direct, High; PMID: 31238208) «✓ PMID:31238208».

How does the stent frame design in the HA-TAV contribute to the reduction of RSS frequency?

What are the differences in velocity vector fields between balloon-expandable and self-expanding transcatheter valves?

How do turbulent stresses correlate with energy loss in novel polymeric heart valve designs?

The "semi-open" leaflet confirmation in the PolyNova valve is designed as the material's nominal or "zero-stress" state to minimize the mechanical fatigue experienced during the cardiac cycle (Direct, High; PMID: 30845067) «✓ PMID:30845067».

Mechanism of Stress Reduction

• Adjustment of the Zero-Stress State: In the PolyNova valve design, the leaflets are manufactured so that their resting, unstressed position is semi-open. This configuration serves as the baseline from which the leaflets must deform to either fully open or fully close (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Minimization of Accumulated Stresses: By setting the zero-stress state at a midpoint, the magnitude of deformation required during both the systolic (opening) and diastolic (closing) phases is reduced compared to a design that starts from a fully closed or fully open position. This helps in "further reducing the accumulated stresses over the cardiac cycle" (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Synergy with Thickness Optimization: This geometric adjustment was integrated with the Device Thrombogenicity Emulation (DTE) methodology. In this process, numerical analysis was used to locally adjust the leaflets' thickness profile—thickening regions of high flexural stress and thinning others—to further maximize durability (Direct, High; PMID: 30845067) «✓ PMID:30845067».

Impact on Durability

• Extended Fatigue Life: This design strategy contributed to the valve's ability to surpass 400 million cycles in accelerated wear testing without failure or significant drops in cardiac parameters such as Effective Orifice Area (EOA) or regurgitation (Direct, High; PMID: 30845067) «✓ PMID:30845067».
• Stable Kinematics: The combination of the semi-open confirmation and xSIBS material properties led to a gradual improvement in hydrodynamic performance over time (reduced pressure gradient and closing regurgitation), which researchers attributed to the "priming" or optimization of leaflet kinematics during continuous cycling (Direct, High; PMID: 30845067) «✓ PMID:30845067».

How does the local thickness adjustment of leaflets in the DTE methodology specifically reduce flexural stresses?

What specific hydrodynamic parameters were measured every 50 million cycles during the PolyNova durability test?

How does the use of xSIBS material complement the semi-open design to prevent plastic deformation during crimping?

The Device Thrombogenicity Emulation (DTE) methodology utilizes rigorous numerical analysis to locally optimize the thickness profile of polymeric leaflets, specifically targeting the reduction of flexural stresses to enhance long-term durability (Direct, High; PMID: 30845067).

Mechanism of Stress Reduction through DTE

• Numerical Stress Analysis: The DTE methodology involves performing detailed simulations to identify the precise distribution of mechanical stresses across the leaflet surface during the full cardiac cycle (Direct, High; PMID: 30845067).
• Targeted Thickening: Regions identified as being subjected to high flexural stresses are locally thickened. This provides greater structural reinforcement in areas most prone to mechanical fatigue (Direct, High; PMID: 30845067, PMID: 35318480).
• Weight and Volume Reduction: Conversely, regions experiencing lower mechanical loads are thinned. This thinning reduces the overall material volume (Direct, High; PMID: 35318480).
• Flexural Stress Minimization: By balancing thickness according to local load requirements, the methodology minimizes the accumulation of flexural cyclic stresses that typically lead to material degradation and leaflet tearing (Direct, High; PMID: 35318480).

Synergy with Valve Geometry

• Nominal State Optimization: The thickness adjustments are integrated with the selection of a "semi-open" nominal confirmation. This ensures that the leaflets are in a zero-stress state at a midpoint, further reducing the deformation needed during opening and closing (Direct, High; PMID: 30845067).
• Hydrodynamic Performance: This local optimization not only addresses structural durability but also improves the valve's hydrodynamics by ensuring the leaflets open and close with optimal kinematics (Direct, High; PMID: 35318480).
• Durability Outcome: Valves optimized using this DTE-based thickness adjustment have successfully surpassed 400 million cycles in durability testing, demonstrating the effectiveness of local stress-based reinforcement (Direct, High; PMID: 30845067).

How do numerical simulations in DTE quantify the thrombogenic potential of heart valve designs?

What are the specific differences in flexural cyclic stresses between first-generation and second-generation polymeric TAVs?

What specific raw materials and molding processes are used to fabricate valves with varying thickness profiles?

Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

• PMID:30845067 — This thinning reduces the overall material volume, which is critical for achieving lower crimped delivery profiles for t...
  Failed: conclusion — While the paper mentions thickening/thinning for stress optimization, it does not explicitly state that thinning reduces overall material volume specifically to achieve lower crimped delivery profiles.

To fabricate polymeric heart valves with varying thickness profiles, researchers utilize specific raw materials combined with high-precision molding techniques that allow for local geometric adjustments as dictated by numerical stress analysis (Direct, High; PMID: 30845067) «✓ PMID:30845067».

xSIBS and Vacuum Compression Molding

The PolyNova valve utilizes a specialized fabrication process to achieve local thickness adjustments based on Device Thrombogenicity Emulation (DTE) analysis (Direct, High; PMID: 30845067) «✓ PMID:30845067» «✓ PMID:30845067».
* Raw Materials: The process starts with raw xSIBS pellets (cross-linked poly(styrene-b-isobutylene-b-styrene)), a modified polyolefin elastomer (Direct, High; PMID: 30845067) «✓ PMID:30845067» «✓ PMID:30845067».
* Molding Process: Fabrication is performed using vacuum compression molding (Direct, High; PMID: 30845067) «✓ PMID:30845067» «✓ PMID:30845067».
* Technical Parameters: Pellets are placed inside a custom-designed mold and processed under:
* Heat: 220 °C.
* Pressure: 4 Tons.
* Duration: 1 hour.
* Vacuum Enhancement: The mold is connected to a vacuum line throughout the curing process to enhance the density and overall quality of the molded polymer (Direct, High; PMID: 30845067) «✓ PMID:30845067» «✓ PMID:30845067».
* Thickness Control: The mold itself is designed to locally adjust the leaflets' thickness profile—thickening regions of high flexural stress and thinning others to minimize accumulated cardiac stresses (Direct, High; PMID: 30845067) «✓ PMID:30845067» «✓ PMID:30845067».

HA-LLDPE and Blow-Molding/Swelling

Another approach involves the creation of interpenetrated networks (IPN), though these are typically processed into sheets before cutting (Direct, High; PMID: 31238208) «✓ PMID:31238208» «✓ PMID:31238208».
* Raw Materials: LLDPE resin (specifically Dowlex 2056) is used as the base polymer (Direct, High; PMID: 31238208) «✓ PMID:31238208» «✓ PMID:31238208».
* Sheet Fabrication: The resin is blow-molded into sheets (e.g., 80 μm thick) (Direct, High; PMID: 31238208) «✓ PMID:31238208».
* Molecular Integration: A swelling process is then used to combine hyaluronan (HA) with the LLDPE at the molecular level, forming an IPN that cannot be separated unless chemical bonds are broken (Direct, High; PMID: 31238208) «✓ PMID:31238208» «✓ PMID:31238208».

Emerging Manufacturing Technologies

Review data identifies several other technologies currently under investigation for polymeric valve fabrication (Direct, High; PMID: 40767293) «✓ PMID:40767293» «✓ PMID:40767293»:
* Injection Molding: Amenable to linear low-density polyethylene (LLDPE) for creating complex geometries with high tensile strength (Direct, High; PMID: 40767293) «✓ PMID:40767293» «✓ PMID:40767293».
* 3D Printing and Micromachining: Emerging methods aimed at accelerating the development of patient-specific heart valve prostheses (Direct, High; PMID: 40767293) «✓ PMID:40767293» «✓ PMID:40767293».
* Electrostatic Spinning: Used to create fibrous scaffolds that can replicate the structural properties of natural valve tissues (Direct, High; PMID: 40767293) «✓ PMID:40767293» «✓ PMID:40767293».

How does vacuum compression molding improve the density and quality of xSIBS heart valves?

What specific laser-cut stent materials are used as frames for molded xSIBS valves?

What are the differences in mechanical strength between blow-molded and injection-molded LLDPE heart valves?